Urology
Volume 61, Issue 1 , Pages 20-22 , January 2003

Informed consent for prostate-specific antigen-based screening—European view

  • Kazuto Ito

      Affiliations

    • Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    • ,
  • Fritz H Schrder

      Affiliations

    • Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    • Corresponding Author InformationReprint requests: Fritz H. Schröder, M.D., Department of Urology, Erasmus University and Academic Hospital, P.O. Box 1738, Rotterdam 3000 DR, The Netherlands

Received 17 July 2002 ,Accepted 24 September 2002.

References 

  1. Schröder FH, et al: Early detection and screening for prostate cancer (ICUD Paris 2002)
  2. Greenlee RT, Hill-Harmon MB, Murray T, et al.  Cancer statistics, 2001. (Erratum in Cancer J Clin 51: 144, 2001) CA Cancer J Clin. 2001;51:15–36
  3. Bartsch G, Horninger W, Klocker H, et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal state of Tyrol, Austria. Urology. 2001;58:417–424
  4. Holmberg L, Bill-Axelson A, Helgesen F, et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789
  5. Lu-Yao GL, Yao SL. Population-based study of longterm survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906–910
  6. Essink-Bot ML, De Koning HJ, Nijs HGT, et al.  Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst. 1998;12:925–931
  7. Madalinska JB, Essink-Bot ML, de Koning HJ, et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19:1619–1628
  8. McGregor M, Hanley JA, Boivin JF, et al.  Screening for prostate cancer (estimating the magnitude of overdetection). Can Med Assoc J. 1998;159:1368–1372
  9. Zappa M, Ciatto S, Bonardi R, et al.  Overdiagnosis of prostate carcinoma by screening (an estimate based on the results of the Florence screening pilot study). Ann Oncol. 1998;9:1297–1301
  10. Schröder FH, Wildhagen MF  ERSPC Study Group . Screening for prostate cancer (evidence and perspectives). BJU Int. 2001;88:811–817
  11. Smith RA, Von Eschenbach AC, Wender A, et al.  American Cancer Society guidelines for the early detection of cancer (update of early detection guidelines for prostate cancer, colorectal, and endometrial cancers). CA Cancer J Clin. 2001;51:38–75
  12. American Urological Association . Prostate-specific antigen best practice policy. Oncology. 2000;14:267–280
  13. Bratt O, Damber JE, Emanuelsson M, et al.  Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer. 2000;36:235–241
  14. Wolf AMD, Nasser JF, Wolf AM, et al.  The impact of informed consent on patient interest in prostatespecific antigen screening. Arch Intern Med. 1996;156:13333–13336
  15. Wolf AMD, Schorling JB. Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent. J Gerontol Med Sci. 1998;53A:M195–M200
  16. Advisory Committee on Cancer Prevention . Recommendations on cancer screening in the European union. Eur J Cancer. 2000;36:1473–1478

PII: S0090-4295(02)02258-6

Urology
Volume 61, Issue 1 , Pages 20-22 , January 2003

Article Tools